Related Experiment Video

Updated: May 22, 2026

Oral Administration of Rotenone using a Gavage and Image Analysis of Alpha-synuclein Inclusions in the Enteric Nervous System
11:53

Oral Administration of Rotenone using a Gavage and Image Analysis of Alpha-synuclein Inclusions in the Enteric Nervous System

Published on: October 26, 2010

Mitochondrial complex I inhibitor rotenone-induced toxicity and its potential mechanisms in Parkinson's disease

Nian Xiong1, Xi Long, Jing Xiong

  • 1Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hubei 430022, China.

Critical Reviews in Toxicology
|May 12, 2012
PubMed

Insights

Rotenone, a pesticide, creates Parkinson's disease (PD) models by inhibiting mitochondrial complex I. These models mimic PD's key features, aiding research into its causes and treatments.

Area of Science:

  • Neuroscience
  • Toxicology
  • Pathology

Background:

  • Parkinson's disease (PD) etiology involves genetic and environmental factors.
  • Key pathological hallmarks include mitochondrial impairment, oxidative stress, and alpha-synuclein aggregation.
  • Pesticide exposure, particularly to mitochondrial toxins, is linked to PD development.

Purpose of the Study:

  • To review rotenone-based models for Parkinson's disease.
  • To discuss the role of mitochondrial dysfunction in PD pathogenesis.
  • To explore potential therapeutic strategies for PD.

Main Methods:

  • Utilizing rotenone, a mitochondrial complex I inhibitor, to create parkinsonian models.
  • Observing dopaminergic neuron loss and Lewy body formation in rotenone models.
  • Comparing rotenone-induced parkinsonism with idiopathic PD features.

Main Results:

  • Rotenone models effectively mimic clinical and pathological features of idiopathic PD.
  • These models recapitulate progressive dopaminergic neuron loss in the nigral-striatal system.
  • Lewy body-like inclusions are observed in rotenone-treated models.

Conclusions:

  • Rotenone-based models are valuable tools for studying PD pathogenesis.
  • Mitochondrial dysfunction induced by agents like rotenone is a significant factor in PD.
  • These models offer insights into potential therapeutic interventions for Parkinson's disease.

More Related Videos

Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing09:02

Protocol for the Differentiation of Human Induced Pluripotent Stem Cells into Mixed Cultures of Neurons and Glia for Neurotoxicity Testing

Published on: June 9, 2017

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease08:09

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...